Opens in a new tab

Tau Blood Test: New JAMA Study Tracks Alzheimer's Stage

Table of Content

Tau blood test research: a lab technician holds a plasma tube next to a brain showing Alzheimer's tangle stages

⚕️ This article is for informational purposes only and does not replace medical advice. Always consult your doctor to interpret your results.

Blood tests for Alzheimer's disease have moved fast. Since 2025, tests that measure p-tau217 can tell doctors whether the hallmark amyloid changes of Alzheimer's are likely present in a person with memory problems. What they cannot do well is say how far the disease has spread in the brain. A study published in JAMA on November 16, 2026, and presented on November 18 at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, describes a tau blood test that tries to answer that second question.

The test measures a fragment of tau protein called eMTBR-tau, which tracks the tangles that build up inside brain cells as Alzheimer's progresses. Here is what the researchers found, what it does not yet mean, and how it fits with the blood tests already in use.

What the new JAMA study tested

The work was led by researchers at Banner Sun Health Research Institute in Arizona and Lund University in Sweden. They used a new immunoassay, developed with antibodies from Bioventix and run on Alamar Biosciences' platform, to measure eMTBR-tau in blood plasma.

Until now, this marker could only be measured by mass spectrometry, a slow and specialized laboratory method that needs about 1.5 mL of plasma. The new assay needs 35 microliters, roughly 40 times less, which makes large studies and, one day, routine testing more realistic.

The team tested 728 people in four research groups:

  • 521 brain donors from Banner's brain and body donation program and the University of California, Irvine, whose blood was compared with the tangles actually found in their brains after death;
  • 207 living people from the TRIAD study in Canada and the BioFINDER-2 study in Sweden, whose blood was compared with tau PET brain scans.

What the researchers found

Blood eMTBR-tau levels rose sharply as tangles spread through the brain. In brain donors, levels were about 25 to 50 times higher at the most advanced tangle stage than at the earliest stages. The rise seen with p-tau217 over the same range was much smaller, about 3 to 5 times.

The test was good at separating people with advanced tangle spread from those with milder spread, and in one of the two autopsy groups it did this better than a standard p-tau217 test. In the other groups, the difference with p-tau217 was not statistically significant. The new assay also gave results very close to the older mass spectrometry method.

Blood markerWhat it mainly reflectsWhen it changesStatus in 2026
p-tau217Presence of Alzheimer's brain changes, especially amyloid plaquesEarly, often years before symptomsFDA-cleared tests used to help diagnose people with symptoms
Amyloid beta 42/40 ratioAmyloid plaquesEarlyOften combined with p-tau217
eMTBR-tauTau tangles inside brain cellsLater, as the disease advancesResearch only, not available for patient care

The authors see the two tau markers as partners rather than rivals: p-tau217 helps show that Alzheimer's is there, and eMTBR-tau could help show how advanced it is. That matters because, as study leader Niklas Mattsson-Carlgren told Reuters, a key challenge is confirming that Alzheimer's changes are advanced enough to be the likely cause of a person's symptoms.

Why staging Alzheimer's with a blood test matters

Many older adults have some amyloid in the brain without ever developing dementia. Tangles, by contrast, follow symptoms much more closely. A blood test that reflects tangle spread could help in three ways:

  • deciding whether Alzheimer's is the likely cause of memory problems, or whether another condition should be looked for;
  • helping doctors judge whether a person is a candidate for amyloid-lowering drugs, which are approved for early-stage disease;
  • choosing participants for, and tracking results in, trials of drugs that target tau.

Today, tangle spread is measured with tau PET scans, which are costly and available in few centers. A blood sample is far easier to collect.

The limits: what this test cannot do yet

  • It is not available for clinical use. Banner Health has given no timeline, and the test is not meant to diagnose Alzheimer's on its own.
  • It cannot grade early disease. In people with little tangle spread, many results were too low to be measured accurately.
  • The study was cross-sectional: it took one snapshot per person. It cannot yet show whether the marker predicts how fast someone will decline.
  • Participants came from research and brain donation programs and were not very diverse, so results may differ in everyday clinics.
  • Several authors have ties to companies that make or license tau tests, which is common in this field but worth knowing.

A separate JAMA study from Washington University in St. Louis, published November 13, 2026, found that eMTBR-tau243 is also raised in some other brain diseases with similar tau, including advanced chronic traumatic encephalopathy (CTE), the condition linked to repeated head impacts. That is a reminder that no single marker tells the whole story.

Which tests can monitor or screen for this?

There is no blood test to screen healthy people for Alzheimer's, and the Alzheimer's Association guideline says blood biomarkers should be used only for people who already have cognitive symptoms, as part of a full evaluation by a specialist. If you or a relative has memory problems, the workup usually includes:

For background, see our guides to Alzheimer's disease and its stages and to what p-tau217 can predict.

Recent scientific advances

Research on tau blood tests has gathered pace over the past two years. A 2025 study in Nature Medicine first showed that eMTBR-tau243 in blood rises with the amount of tau tangles and with the severity of memory and thinking problems. In 2026, a study of the Swedish BioFINDER-2 group mapped when each blood marker changes: p-tau217 moves first, near the time amyloid appears, while eMTBR-tau changes later, closer to the time tangles spread and symptoms worsen.

In practical terms, researchers are building a set of blood tests that work like a timeline: one marker says the disease process has started, another says how far it has gone. The new JAMA immunoassay is a step toward making the second marker easy enough to measure outside a few specialized labs. In 2024, the Alzheimer's Association had already updated its diagnostic criteria to include biological staging, which gives such tests a natural place if they are confirmed.

When to see a doctor

  • Memory loss that affects daily life, such as repeating questions or getting lost in familiar places.
  • Trouble planning, handling money, finding words or following a conversation.
  • Changes in mood, personality or judgment noticed by family or friends.
  • Sudden confusion, which needs urgent care because it often has another cause, such as an infection, a medication side effect or a stroke.

Glossary

  • Tau tangles: twisted threads of tau protein that build up inside brain cells in Alzheimer's disease and spread through the brain in stages.
  • eMTBR-tau: a fragment of tau containing its microtubule-binding region, found in blood, that reflects tangles.
  • p-tau217: a form of tau with a phosphate group at position 217; its blood level rises early in Alzheimer's.
  • Amyloid plaques: clumps of amyloid beta protein between brain cells, one of the two hallmarks of Alzheimer's.
  • Braak stage: a scale from I to VI that describes how far tangles have spread in the brain.
  • Tau PET: a brain scan that uses a tracer to show where tangles are located.
  • Immunoassay: a laboratory test that uses antibodies to detect and measure a specific protein.

FAQ

Can I get the eMTBR-tau blood test now?

No. It is a research test. It has not been cleared by the FDA and is not offered for patient care.

Is this different from the Alzheimer's blood tests already available?

Yes. Current tests, mostly based on p-tau217 and amyloid, show whether Alzheimer's changes are likely present. eMTBR-tau aims to show how far tau tangles have spread, which is closer to the stage of the disease.

Can a blood test tell me what stage of Alzheimer's I have?

Not yet. Stage is judged today by a doctor from symptoms, daily function and sometimes scans. Tau blood tests may help with biological staging in the future, after larger studies.

Should healthy people get an Alzheimer's blood test?

Experts do not recommend it. Current guidance limits these tests to people with memory or thinking problems who are being evaluated by a specialist.

Can other conditions affect tau blood tests?

Yes. Reduced kidney function can raise p-tau217, and eMTBR-tau243 can also be raised in some other brain diseases, such as advanced CTE. Results always need medical interpretation.

Sources

Other articles

Understand your own blood test results with AI DiagMe

Have a recent blood test with values outside the normal range, such as B12, thyroid or kidney markers? Upload your lab report to AI DiagMe to get a clear, plain-language explanation of each result in minutes, and prepare your questions for your doctor.

Editorial team

  • AI DiagMe

    Author

    The AI DiagMe team brings together physicians, clinical specialists, and medical editors. Our articles are written by health communication professionals and then reviewed and validated by the physicians of our scientific committee, composed of practicing hospital physicians in specialties such as hematology, endocrinology, and general medicine. Julien Priour, who leads the editorial mission, holds an MBA from HEC Paris and was trained in scientific writing and publishing by the French National Research Institute for Sustainable Development (IRD, FUN-MOOC, 2026). Each piece of content is based on current clinical guidelines and peer-reviewed medical publications.

    Email Website
  • Julien Priour

    Edited by

    Co-founder and CEO of AI DiagMe · Senior medical editor · HEC Paris graduate

    Julien Priour is a senior medical editor at AI DiagMe, where he oversees the editorial line and the fact-checking process. A graduate of HEC Paris, he has 3 years of experience in health publishing and was trained in scientific writing and publishing by the French National Research Institute for Sustainable Development (IRD, FUN-MOOC, 2026). He makes sure that every article follows current medical guidelines and is reviewed and validated by a physician from the scientific and ethics committee. He sets the sourcing standards (HAS, Ameli, INSERM…) and the review standards applied across the entire site.

    Email LinkedIn
  • Dr. Claude Tchonko

    Medically reviewed by

    Dr. Claude Tchonko is a hematologist, in practice since 2013, currently working at Clinique Mas de Rochet (Castelnau-le-Lez, France). With an international background, he specializes in the management of hematologic malignancies (leukemias, lymphomas, myelomas), with particular expertise in autologous stem cell transplantation, CAR-T cell therapy and the optimization of care pathways in onco-hematology.

    Author of a reference work, “Lymphoid Hematologic Malignancies in Mali”, he combines clinical practice with active involvement in projects developing technology solutions for healthcare.

    He holds a State Doctorate in Medicine (Faculty of Medicine of Bamako, 2006) and completed his training with a Certificate of Specialized Studies in Bioclinical Hematology (Abidjan-Cocody, 2010) and several university diplomas: a DFMS in Hematology and an inter-university diploma (DIU) in Onco-Hematological Cytogenetics (Grenoble), as well as a university diploma (DU) in major sickle cell disease (UPEC).

    Dr. Claude Tchonko LinkedIn

Related Posts

Coming Soon